Cyclo Therapeutics, Inc. , a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today. | June 5, 2023
GAINESVILLE, Fla. (BUSINESS WIRE) Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has entere.
Company on track to complete enrollment in ongoing pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 by year end 2023
. | May 15, 2023
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cyclo Therapeutics (CYTH) Provides Clinical Program Update and Highlights Recent Achievements streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.